EFOWEDER ceipt date: 06/16/2004

6/17/04

IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (B&W No. 003979-00002)

Applicant:

Weaver, et al.

Serial No.:

10/800,587

Filing Date:

March 15, 2004

Examiner:

Unassigned

Group:

3763

Conf. No.:

1652

Title:

CERTIFICATE OF EXPRESS MAIL

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Express Mail Receipt No. <u>EV436814039US</u>

Date of Deposit: June 16, 2004

I hereby state that the following:

- **X** Information Disclosure Statement
- **X** PTO-1449 Form
- X Copies of Art as Cited on Page 1-2 of PTO-1449 Form
- X Return Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, on the date indicated above and is addressed to Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Brigid Laffey

June 16, 2004

Dated

Drond Lappen

Signature of person mailing above-identified papers



Docket No. 003979/00002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Weaver, et al.

EXAMINER: Unassigned

SERIAL NO.:

10/800,587

GROUP:

3763

FILED:

15 March 2004

CONF. NO.: 1652

FOR:

Microscission Process and Procedure

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56 and §1.97, Applicant herewith submits the publications and/or patents shown on the attached Form PTO-1449, for consideration by the Examiner in connection with the examination of the aboveidentified patent application.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed within three (3) months of the Filing Date or before the mailing date of the First Office Action on the merits

It is respectfully requested that each of the documents shown on the attached form PTO-1449 be made of record in this application. Copies of these documents are in the file of related application Serial No. 09/878,155, filed 07 June 2001 and are thus not being resubmitted herein.



Information Disclosure Statement U.S.S.N. 10/800,587 Page 2 of 2

Early examination and allowance of the present application are respectfully solicited.

FEE AUTHORIZATION

Any fee associated with this submission should be charged to our Deposit Account - No. 19-0733.

CERTIFICATE OF EXPRESS MAIL FILING

The undersigned hereby certifies that this correspondence is being deposited by Express Mail, Express Mail Receipt No. EV 436814039 in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 16, 2004.

Respectfully submitted,

Ernest V. Linek (Reg. No. 29,822)

Áttorney for Applicant

BANNER & WITCOFF, LTD.

28 State Street, 28th Floor

Boston, MA 02109-1775

Tel: (617) 720-9600 Fax: (617) 720-9601

E-mail: ELinek@bannerwitcoff.com

Date: 16 June 2004

TO TO ADS

PTO/SB/08a (05-03) Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known 10/800,587 **Application Number** MFORMATION DISCLOSURE Filing Date March 15, 2004 STATEMENT BY APPLICANT James C. Weaver First Named Inventor Art Unit 3763 (use as many sheets as necessary) **Examiner Name** Not Yet Assigned Sheet 003979-00002 of 8 Attorney Docket Number

			U.S. PATENT	DOCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan
Initials *	· Cite No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	GIIG GOODING.	Passages or Relevant Figures Appear
/BM/		US- 6,706,032	03/16/2004	James C. Weaver et al.	
	Ī	US-			
		US-			
		US-			
	T	US-			
		US-			- 1

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	۳°
		WO 01/93947 A1	12/13/01	James C. Weaver et al.		
-						
<u> </u>						

Examiner Signature	/Bhisma Mehta/	Date Considered	06/16/2008	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ute for form 1449A/PTO

PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

隊FORMATION DISCLOSURE ATEMENT BY APPLICANT

(use as many sheets as necessary)

8 Sheet 2 of

ı	Complete if Known	
Application Number	10/800,587	
Filing Date	March 15, 2004	
First Named Inventor	James C. Weaver	
Group Art Unit	3763	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	003979-00002	

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
/BM/		TERRY O HERNDON et al., Transdermal microconduits by microscission for drug delivery and sample acquisition, BMC Medicine 2004, 2:12, April 19, 2004			

Examiner Signature	/Bhisma Mehta/	Date Considered	06/16/2008
-----------------------	----------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PHILIP TO ANG

3763

Not Yet Assigned 003979-00002

PTO/SB/08a (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. set titute for form 1449A/PTO Complete if Known Application Number 10/800,587 JUN 1 6 2004 INFORMATION DISCLOSURE March 15, 2004 Filing Date First Named Inventor James C. Weaver

Art Unit

Examiner Name

TATEMENT BY APPLICANT

(use as many sheets as necessary)

of Attomey Docket Number 8 Sheet 3

EXAM- INER INI- FIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
/BM/	AC2	5,630,796	20 May 97	Bellhouse, et al.	604	49	
<u> </u>						1	
	-						
·							
						8	
	l		FOREIG	N PATENT DOCUMENTS			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
/BM/	AM	WO 00/03758	27 Jan 00	PCT		<u> </u>	
/BM/	AN	WO 97/04832	13 Feb 97	PCT			
/BM/	AO	EO 0 417 290	20 Mar 91	EPO			
	AP					<u></u>	
	AQ						
_		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertine	nt Pages,	Etc.)	
	AR			· · · · · · · · · · · · · · · · · · ·			
	AS						
			- 				
	AT						

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

JUN 1 6 2014 STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete It Known					
Application Number	10/800,587				
Filing Date	March 15, 2004				
First Named Inventor	James C. Weaver				
Art Unit	3763				
Examiner Name	Not Yet Assigned				
Attorney Docket Number	003979-00002				

۰							
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
/BM/	AA	5,019,034	05/28/1991	Weaver, et al.	604	20	
/BM/	AB	5,389,069	02/14/1995	Weaver	604	21	
/BM/	AC	6,085,115	07/04/2000	Weaver, et al.	600	509	
/BM/	AD	5,003,987	04/02/1991	Grinwald	128	734	
/BM/,	AE	5,688;233	11/18/1997	Hofmann, et al.	604	20	
/BM/	AF.	5,885,211	03/23/1999	Eppstein, et al.	600	309	
/BM/	AG	6,142,939	11/07/2000	Eppstein, et al.	600	309	
/BM/	HA	6,022,316	02/08/2000	Eppstein, et al.	600	309	
/BM/	AI	5,547,467	08/20/1996	Pliquett, et al.	604	20%	
/BM/	AJ	5,667,491	09/16/1997	Pliquett, et al.	604	50	
/BM/	AK	5,749,847	05/12/1998	Zewert, et al.	604	49	
/BM/	AA2	5,911,223	06/15/1999	Weaver, et al.	128	898	
/BM/	AE2	5,983,131	11/09/1999	Weaver, et al.	604	20	-
			FOREIGN	PATENT DOCUMENTS			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
/BM/	AL	WO 97/07734	03/06/1997	PCT			
		OTHER DOCUMENTS	(Including Auth	or, Title, Date, Pertinent	Pages, i	Stc.)	
	AR	Langer, R., "Dru	ng Delivery a	and Targeting.," Natur	e, 392:	S5-S10	(1998).
/BM/	AS			neous Transport in Re Composition," J. Inve			
·/BM/	AT	Elias, P.M., and Menon, G.K., "Structural and Lipid Biochemical Correlates of the Epidermal Permeability Barrier," Adv. Lipid Res., 24: 1-26 (1991).					
/BM/	Zewert, T.E., et al., "Creation of Transdermal Pathways for Macromolecule Transport by Skin Electroporation and a Low Toxicity, Pathway-Enlarging Molecule," Bioelectrochem. and Bioenerget., 49:11-20 (1999).						
/BM/	/BM/ Ilic, L., et al., "Electrochemical Creation of Microconduits in Full-Thickness Human Skin for Transdermal Drug Delivery by Pressure-Driven Flow," Proc. Internat. Symp. on Controlled Release of Bioact. Materials, Controlled Release Society, 26:178-179 (1999).						
EXAMIN		/Bhisma Mehta/		DATE CONSIDERED 06/16/20	800		

1 HUL

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO MATION DISCLOSURE TATEMENT BY APPLICANT

> (use as many sheets as necessary) of

	Complete if Known	SCHOOL HOLLIDGE
Application Number	10/800,587	
Filing Date	March 15, 2004	
First Named Inventor	James C. Weaver	
Art Unit	3763	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	003979-00002	

		U.S. PATENT DOCUMENTS
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
/BM/	AW	Ilic, L., et al., "Spatially Constrained Skin Electroporation with Sodium Thiosulfate and Urea Creates Transdermal Microconduits," J. Control. Release, 61:185-202 (1999).
/BM/	AX	Yamashita, N., et al., "Scanning Electron Microscopic Evaluation of the Skin Surface after Ultrasound Exposure," The Anatomical Record, 247: 455-461 (1997).
/BM/	AY	Tachibana, K., and Tachibana, S., "Transdermal Delivery of Insulin by Ultrasonic Vibration," J. Pharm. Pharmacol., 43(4):270-271 (1991).
/BM/	AZ	Mitragotri, S., et al., "Ultrasound-Mediated Transdermal Protein Delivery," Science, 269:850-853 (1995).
/BM/	AR2	Mitragotri, S., et al., "Determination of Threshold Energy Dose for Ultrasound-Induced Transdermal Drug Transport," J. Controlled Release, 63:41-52 (2000).
/BM/	AS2	Jacques, S.L., et al., "Controlled Removal of Human Stratum Corneum by a Pulsed Laser," J. Invest. Dermatol., 88(1):88-93 (1987).
/BM/	AT2	Nelson, J.S., et al., "Mid-Infrared Laser Ablation of Stratum Corneum Enhances in Vitro Percutaeous Transport of Drugs," J. Invest. Dermatol., 97(5):874-879 (1991).
/BM/	AU2	Eisenbraun, M.D., et al., "Examination of Parameters Affecting the Eliciation of Humoral Immune Responses by Particle Bombardment-Mediated Genetic Immunization," DNA and Cell Biology, 12(9):791-797 (1993).
/BM/	AV2	Macklin, M.D., et al., "Immunization of Pigs with a Particle-Mediated DNA Vaccine to Influenza A Virus Protects Against Challenge with Homologous Virus," J. of Virology, 72(2):1491-1496 (1998).
/BM/	AW2	Smith, A., et al., "Fluorescein Kinetics in Interstitial Fluid Harvested from Diabetic Skin During Fluorescein Angiography: Implications for Glucose Monitoring," Diabetes Tech. & Therapeut., 1(1): 21-27 (1999).
/BM/	AX2	Cullander, C., "What Are the Pathways of Iontophoretic Current Flow Through Mammalian Skin?" Adv. Drug Delivery Rev., 9(2/3):119-135 (1992).
/BM/	AY2	Inada, H., et al., "Studies on the Effects of Applied Voltage and Duration on Human Epidermal Membrane Alteration/recovery and the Resultant Effects upon Iontophoresis," Pharm. Res., 11(5):687-697 (1994).
/BM/	AZ2	Green, P.G., "Iontophoretic Delivery of Peptide Drugs," J. Controlled Release, 41:33-48 (1996).

EXAMINER

PTO/SB/08a (05-03)

EFS-Web Receipt date: 06/16/2004

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JUN 1

Substitute for form 1449A/PTO Complete if Known Application Number 10/800,587 INFORMATION DISCLOSURE Filing Date March 15, 2004 TEMENT BY APPLICANT First Named Inventor James C. Weaver Art Unit 3763 (use as many sheets as necessary) Examiner Name Not Yet Assigned of 8. Attorney Docket Number 003979-00002

		OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)			
/BM/	AR3	Merino, V., et al., "Tran Iontophoresis," TIBTech.,	Merino, V., et al., "Transdermal Therapy and Diagnosis by Iontophoresis," TIBTech., 15:288-290 (1997).			
/BM/	AS3	Dinh, S.M., et al., "Uppe Resistance in Iontophores	r and Lower Limits of Human Skin Electrical is," AIChE J., 39(12) :2011-2018 (1993).			
/BM/	АТЗ	Iontophoretic Drug Deliver	t al., "Identification of the Pathway of ry: Light and Ultrastructure Studies Using ," Pharm. Res., 11(2):251-256 (1994).			
/BM/	AU3	Langkjaer, L., et al., "Id Vitro: Effects of Insulin Release, 51:47-56 (1998).	ontophoresis of Monomeric Insulin Analogues In Charge and Skin Pretreatment," J. Control.			
/BM/	AV3	CIII ZMA ZIIEV, I., EL AI.,	Electrical Properties of Skin at Moderate Appendageal Macropores," Biophys. J., 74:			
/BM/	AW3	Prausnitz, M.R., et al., "Electroporation of Mammalian Skin: A Mechanism to Enhance Transdermal Drug Delivery," Proc. Nat. Acad. Sci. USA, 90:10504-10508 (1993).				
/BM/	АХЗ	Prausnitz, M.R., et al., " Using Surface Electrodes,"	Methods for in Vivo Tissue Electroporation Drug Delivery, 1(2):125-131, (1993).			
/BM/	АУЗ	Gallo, S.A, et al., "Characterization of Electric-Pulse-Induced Permeabilization of Porcine Skin Using Surface Electrodes," Biophysical Journal, 72: 2805-2811 (1997).				
/B M /	A23	Skin after High-Voltage Pu	Vanbever, R., et al., "In vivo Noninvasive Evaluation of Hairless Rat Skin after High-Voltage Pulse Exposure," Skin Pharmacol. Appl. Skin Physiol., 11:23-34 (1998).			
/BM/	AR4	Vanbever, R., et al., "Tra of Analgesia Using Skin El 225-235 (1998).	nsdermal Delivery of Fentanyl: Rapid Onset ectroporation," J. Controlled Release, 50:			
/B M /	AS4	Chen, T., et al., "Skin Electroporation Causes Molecular Transport Across the Stratum Corneum Through Localized Transport Regions," J. Invest. Dermatol. Symposium Proceedings, 3:159-165 (1998).				
/BM/	AT4	Chen, T., et al., "Skin Electroporation: Rapid Measurements of the Transdermal Voltage and Flux of Four Fluorescent Molecules Show a Transition to Large Fluxes near 50 V," J. of Pharm. Sci., 87(11):1368-1374 (1998).				
/BM/	AU4	VanBever, R., et al., "Comparison of the Effects of Short, High-voltage and Long, Medium-Voltage Pulses on Skin Electrical and Transport Properties," J. Controlled Release, 69:35-47, (1999).				
/BM/	AV4	Zewert, T.E., et al., "Transdermal Transport of DNA Antisense Oligonucleotides by Electroporation. Biochem. Biophy. Res. Comm., 212(2): 286-292 (1995).				
EXAMIN		/Bhisma Mehta/	DATE CONSIDERED 06/16/2008			

Approved for use through 04/30/2003. OMB 0651-0031

EFS-Web Receipt date: 06/16/2004

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. DEPARTMENT OF COMMERCE OF The Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO ENFORMATION DISCLOSURE

Complete if Known **Application Number** 10/800,587 Filing Date March 15, 2004 First Named Inventor James C. Weaver Art Unit 3763 **Examiner Name** Not Yet Assigned Attorney Docket Number 003979-00002

STATEMENT BY APPLICANT 6 2004 W

(use as many sheets as necessary) of

Sheet

JUH 1

		1 0 6	Attorney Docket Number 003979-00002	
DADE		Ū.S	. PATENT DOCUMENTS	
		OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)	
/BM/	AW4	Prausnitz, M.R., et al., "Transdermal Delivery of Heparin by Skin Electroporation," Biotechnology, 13: 1205-1209 (1995).		
/BM/	AX4	Heise, H.M., "Non-Invasive Monitoring of Metabolites Using Near Infrared Spectroscopy: State of the Art," Horm. Metab. Res., 28:527-534 (1996).		
/BM/	AY4	Fischer, U., et al., "Assessment of Subcutaneous Glucose Concentration: Validation of the Wick Technique as a Reference for Implanted Electrochemical Sensors in Normal and Diabetic Dogs," Diabetologia, 30(12):940-945 (1987).		
/BM/	AZ4	Quan, K.M., et al., "Glucose Determination By a Pulsed Photoacoustic Technique: An Experimental Study Using A Gelatin-Based Tissue Phantom," Phys. Med. Biol., 38(12):1911-1922, (1993).		
/BM/	AR5	Tamada, J.A., et al., "Measurement of Glucose in Diabetic Subjects Using Noninvasive Transdermal Extraction," Nature Medicine, 1(11):1198-1202 (1995).		
/BM/	AS5	Ito, N., et al., "Transcutaneous Blood Glucose Monitoring System Based on ISFET Glucose Sensor and Studies on Diabetic Patients," Frontiers Med. Biol. Engng., 6(4):269-280 (1995).		
/BM/	AT5	Berger, A.J., "Feasibility of Measuring Blood Glucose Concentration by Near-infrared Raman Spectroscopy," Spectochim. Acta, 53(Part A):287-292 (1997).		
/BM/	AU5	Schiffman, et al., "Airway Humidification in Mechanically Ventilated Neonates and Infants: A Comparative Study of a Heat and Moisture Exchanger vs. a Heated Humidifier Using a New Fast-response Capacitive Humidity Sensor," Crit. Care Med. 25(10):1755-1760 (1997).		
/BM/	AV5	Ohhashi, et al., "Human Perspiration Measurement," Physiol. Meas. 19(4): 449-461 (1998).		
/BM/	AW5	Pliquett, U.F., et al. "Imaging of Fluorescent Molecules and Small Ion Transport Through Human Stratum Corneum During High-Voltage Pulsing: Localized Transport Regions Are Involved," J. Biophys. Chem., 58:185-204, (1996).		
/BM/	AX5	Prausnitz, M.R., et al., "Imaging Regions of Transport Across Human Stratum Corneum During High Voltage and Low Voltage Exposures," J. Pharm. Sci., 85(12):1363-1370, (1996).		
/BM/	AY5	Weaver, J.C., et al. "Theory of Electrical Creation of Aqueous Pathways Across Skin Transport Barriers," Advanced Drug Delivery Reviews, 35(1):21-39, (1999).		
/B M /	A25	Gowrishankar, T.R., et. al., "Spatially Contrained Localized Transport Regions Due to Skin Electroporation," J. controlled Release, 60(1): 101-110 (1999).		
EXAMIN	IER	/Bhisma Mehta/	DATE CONSIDERED 06/16/2008	

PTO/SB/08a (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known **Application Number** 10/800,587 INFORMATION DISCLOSURE Filing Date March 15, 2004 STATEMENT BY APPLICANT First Named Inventor James C. Weaver Art Unit 3763 (use as many sheets as necessary) **Examiner Name** Not Yet Assigned 8 of Attorney Docket Number 003979-00002

		The state of the s	the same of the sa	
<u></u>		OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)	
/BM/	AR6	Hikima, T., et al., "Effect of Ultrasound Application on Skin Metabolism of Prednisolone 21-Acetate," Pharm. Res., 15(11):1680-1683 (1998).		
/BM/	AS6	Wu, J., et al., "Defects Generated in Human Stratum Corneum Specimens by Ultrasound," Ultrasound in Med. & Biol. 24(5):705-710 (1998).		
/BM/	AT6	Henry, S., et al., "Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery," J. Pharm. Sci. 87(8):922-925 (1998).		
/BM/	AU6	Miyajima, et al., "Effect of Polymer/Basic Drug Interaction on the Two-Stage Diffusion-Controlled Release from a Poly(L-lactic Acid) Matrix," J. Controlled Rel. 61(3):295-304 (1999).		
/BM/	AV6	Simon, L.D., et al., "Mechanisms Controlling Diffusion and Release of Model Proteins Through and From Partially Esterified Hyaluronic Acid Membranes," J. Controlled Rel. 61(3):267-279 (1999).		
/BM/	AW6	Prestwich, G.D., et al., "Controlled Chemical Modification of Hyaluronic Acid: Synthesis, Applications, and Biodegradation of Hydrazide Derivatives," J. Control. Release 53:93-103 (1998).		
/BM/	AX6			
/BM/	AY6			
/BM/	A26	Longridge, D.J., et al., Effects of Payload Per Unit Area on Dermal Powderject Delivery of Testosterone to Conscious Rabbits," Proceed. Int'l. Symp. Control. Rel. Bioact. Mater., 25:595-596 (1998).		
/BM/	AR7	Uchida, M., et al., "Transdermal Microparticle Delivery by a Supersonic. Helios™ Gun System," Proceed. Int'l. Symp. Control. Rel. Bioact. Mater., 25:575-576 (1998).		
/BM/	AS7	Sage, B.H., Jr., "Iontophoresis" CRC Press, Inc., Chapter 15.1 Percutaneous Penetration Enhancers 351-368 (1995).		
/BM/	AT7	Weaver, J.C., and Langer, R., "Electrochemical Creation of Large Aqueous Pathways: an Approach to Transdermal Drug Delivery," Progress in Dermatology, 33:1-10 (1999).November 26, 2001		
/BM/	AU7	McAllister, D.V., et al., "Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery," Proceed. Int'l. Symp. Control. Rel. Bioact. Mater., 25:30-31 (1998).		
/BM/	AV7	Scott, E.R., et al., "Direct Imaging of Ionic Pathways in Stratum Corneum Using Scanning Electrochemical Microscopy," Solid State Ionics, 53-56(Part 1):176-183 (1992).		
/BM/		Weaver, J.C. and Langer, R. "Electrochemical Creation of Large Aqueous Pathways: an Approach to Transdermal Drug Delivery," Progress in Dermatology, 33: 1-10 (1999)		
DATE CONSIDERED 06/16/2008				